BMS 710485
Modify Date: 2025-08-27 11:10:50
BMS 710485 structure
|
Common Name | BMS 710485 | ||
|---|---|---|---|---|
| CAS Number | 194468-36-5 | Molecular Weight | 1117.103 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C53H66F2N4O20 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BMS 710485Vinflunine ditartrate is the first fluorinated microtubule inhibitor belonging to the Vinca alkaloids family. Vinflunine ditartrate has anti-angiogenic, vascular-disrupting and anti-metastatic activities. Vinflunine ditartrate can be used for the research of transitional cell carcinoma of the urothelial tract, non-small cell lung cancer, and carcinoma of the breast[1][2]. |
| Name | Vinflunine ditartrate |
|---|---|
| Synonym | More Synonyms |
| Description | Vinflunine ditartrate is the first fluorinated microtubule inhibitor belonging to the Vinca alkaloids family. Vinflunine ditartrate has anti-angiogenic, vascular-disrupting and anti-metastatic activities. Vinflunine ditartrate can be used for the research of transitional cell carcinoma of the urothelial tract, non-small cell lung cancer, and carcinoma of the breast[1][2]. |
|---|---|
| Related Catalog | |
| Target |
microtubule[1] |
| In Vitro | Vinflunine (0.01-10 μM; 45 min) induces a rapid change in endothelial cell shape: cells retracted and assumed a rounded morphology[2]. Vinflunine (0.01-10 μM; 1 h) disrupts newly formed capillary-like structures[2]. Vinflunine (0.01-10 μM; 1 h) inhibits endothelial cell motility, with an IC50 of 0.71 μM[2]. Vinflunine (0.001-10 μM; 1-72 h) inhibits endothelial cell proliferation in vitro[2]. |
| In Vivo | Vinflunine (0.08-20 mg/kg; i.v.) reduces the number of experimental liver metastases by human LS174T colon cancer cells[2]. Vinflunine (0.63-5 mg/kg; i.v. before and 2 d after Matrigel implantation) inhibits the bFGF-induced angiogenic response in mice in a dose-dependent manner[2]. Animal Model: Female athymic nude mice (BALB/c/Ola/Hsd-nu) were implanted LS174T cells[2] Dosage: 0.08, 0.16, 1.25, 5, 10, 20 mg/kg Administration: I.v. on days 4, 7, 11, 14, 18 and 21 after tumour cell implantation Result: Induced a dose-dependent reduction in the number of metastatic foci at the surface of the liver and was well tolerated. |
| References |
| Molecular Formula | C53H66F2N4O20 |
|---|---|
| Molecular Weight | 1117.103 |
| Exact Mass | 1116.423828 |
| InChIKey | YIHUEPHBPPAAHH-UHFFFAOYSA-N |
| SMILES | CCC12C=CCN3CCC4(c5cc(C6(C(=O)OC)CC7CC(C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)C4C(O)(C(=O)OC)C1OC(C)=O)C32.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O |
| Vinflunine ditartrate |
| Javlor |
| (2R,3R)-2,3-Dihydroxysuccinic acid - methyl (2β,3β,4β,5α,12β,19α)-4-acetoxy-15-[(12S,14S,16R)-16-(1,1-difluoroethyl)-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.03,11.04,9 ]octadeca-3(11),4,6,8-tetraen-12-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate (2:1) |
| Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(4R,6S,8S)-4-(1,1-difluoroethyl)-1,3,4,5,6,7,8,9-octahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16 ;-methoxy-1-methyl-, methyl ester, (2β,3β,4β,5α,12β,19α)-, compd. with (2R,3R)-2,3-dihydroxybutanedioic acid (1:2) |